Hsueh W A, Buchanan T A
Department of Medicine, University of Southern California Medical Center.
Endocrinol Metab Clin North Am. 1994 Jun;23(2):405-27.
Obesity is associated with a spectrum of metabolic and cardiovascular disorders, including hypertension. Both the degree and the distribution of excess adipose tissue impact on the risk of hypertension and associated cardiovascular diseases. The mechanisms that may lead to hypertension in obese individuals include increased SNS activity, insulin resistance and hyperinsulinemia, sodium retention, and enhanced vascular reactivity. These abnormalities are interrelated in a complex fashion, making it difficult to determine which, if any, of them is the primary process leading to elevated blood pressure in obese individuals. Nonetheless, the metabolic abnormalities and hypertension diminish with weight loss and chronic exercise, providing a strong rationale for hypocaloric diets and aerobic exercise in the treatment of obesity-related hypertension. Patients who fail to achieve acceptable blood pressure control with diet and exercise therapy require pharmacologic treatment. Of the available antihypertensive agents, calcium entry blockers, ACE inhibitors, and alpha 1-receptor blockers appear to offer good blood pressure control without worsening--and sometimes while improving--the lipid and carbohydrate abnormalities that often occur in obese patients. New drugs developed to ameliorate insulin resistance show promise as antihypertensive agents as well, and may prove to be ideal in reversing multiple cardiovascular risk factors in obese, hypertensive patients.
肥胖与一系列代谢和心血管疾病相关,包括高血压。过多脂肪组织的程度和分布均会影响高血压及相关心血管疾病的风险。肥胖个体中可能导致高血压的机制包括交感神经系统(SNS)活性增加、胰岛素抵抗和高胰岛素血症、钠潴留以及血管反应性增强。这些异常以复杂的方式相互关联,使得难以确定其中哪一个(如果有的话)是导致肥胖个体血压升高的主要过程。尽管如此,随着体重减轻和长期运动,代谢异常和高血压会减轻,这为采用低热量饮食和有氧运动治疗肥胖相关高血压提供了有力的理论依据。通过饮食和运动疗法未能实现可接受的血压控制的患者需要药物治疗。在现有的抗高血压药物中,钙通道阻滞剂、血管紧张素转换酶(ACE)抑制剂和α1受体阻滞剂似乎能有效控制血压,且不会恶化——有时甚至会改善——肥胖患者常出现的脂质和碳水化合物异常情况。为改善胰岛素抵抗而研发的新药也显示出作为抗高血压药物的前景,并且可能被证明是逆转肥胖高血压患者多种心血管危险因素的理想药物。